Cancer Chemotherapy
This is not the most recent version, view other versions
This version
Cancer Chemotherapy
Bernhard Kutscher, Gregory A. Curt, Carmen J. Allegra, Robert L. Fine, Hamza Mujagic, Grace Chao Yeh, Bruce A. Chabner,
Bernhard Kutscher,
Gregory A. Curt,
Carmen J. Allegra,
Robert L. Fine,
Hamza Mujagic,
Grace Chao Yeh,
Bruce A. Chabner,
Bernhard Kutscher
ASTA Medica AG, Frankfurt am Main, Federal Republic of Germany
Search for more papers by this authorGregory A. Curt
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorCarmen J. Allegra
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorRobert L. Fine
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorHamza Mujagic
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorGrace Chao Yeh
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorBruce A. Chabner
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorBernhard Kutscher,
Gregory A. Curt,
Carmen J. Allegra,
Robert L. Fine,
Hamza Mujagic,
Grace Chao Yeh,
Bruce A. Chabner,
Bernhard Kutscher
ASTA Medica AG, Frankfurt am Main, Federal Republic of Germany
Search for more papers by this authorGregory A. Curt
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorCarmen J. Allegra
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorRobert L. Fine
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorHamza Mujagic
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorGrace Chao Yeh
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorBruce A. Chabner
National Cancer Institute, Bethesda, Maryland, United States, 20205
Search for more papers by this authorFirst published: 15 June 2000
Abstract
The article contains sections titled:
1. |
Introduction |
2. |
Antimetabolites |
2.1. |
Methotrexate |
2.1.1. |
Mechanism of Action and Mechanisms of Resistance |
2.1.2. |
Analogs |
2.2. |
Fluoropyrimidines |
2.2.1. |
Mechanism of Action |
2.2.2. |
Mechanisms of Resistance |
2.2.3. |
Other Fluoropyrimidines |
2.3. |
5-Azacytidine |
2.3.1. |
Mechanism of Action |
2.3.2. |
Mechanism of Resistance |
2.3.3. |
New Analogs |
2.4. |
Cytosine Arabinoside (Ara-C) |
2.4.1. |
Mechanisms of Resistance |
2.4.2. |
New Analogs |
2.5. |
Deoxycytidine and Analogs |
2.6. |
2-Halopurines and Analogs |
2.7. |
6-Mercaptopurine and 6-Thioguanine |
2.7.1. |
Mechanism of Action |
2.7.2. |
Mechanism of Resistance |
2.7.3. |
New Analogs |
3. |
Alkylating Agents |
3.1. |
Nitrogen Mustard |
3.1.1. |
Mechanism of Action |
3.1.2. |
Mechanisms of Drug Resistance |
3.2. |
Melphalan |
3.2.1. |
Mechanism of Action |
3.2.2. |
Mechanism of Resistance |
3.3. |
Cyclophosphamide |
3.3.1. |
Mechanism of Action |
3.3.2. |
Mechanism of Resistance |
3.4. |
Chlorambucil |
3.5. |
Thio-TEPA |
3.6. |
Ifosfamide |
3.7. |
Estramustine |
3.8. |
Nitrosoureas |
3.8.1. |
Mechanism of Action |
3.8.2. |
Mechanisms of Resistance |
3.8.3. |
Analogs |
3.9. |
Procarbazine |
3.9.1. |
Mechanism of Action |
3.9.2. |
Mechanisms of Resistance |
3.10. |
Dacarbazine |
3.11. |
Hexamethylmelamine |
3.12. |
Mitomycin-C |
4. |
Anthracyclines |
4.1. |
Mechanism of Action |
4.2. |
Mechanism of Resistance |
4.3. |
Analogs |
5. |
Intercalating Anthracenes and Analogs |
5.1. |
Mitoxantrone |
5.2. |
Analogs |
6. |
Antitumor Antibiotics Other than Anthracyclines |
6.1. |
Actinomycin D |
6.2. |
Bleomycin |
6.2.1. |
Analogs |
6.2.2. |
Mechanism of Action |
6.3. |
DNA Interactive Natural Products |
7. |
Antitubulin Agents |
7.1. |
Vinca Alkaloids |
7.1.1. |
Vincristine and Vinblastine |
7.1.2. |
Vindesine |
7.1.3. |
Vinorelbine |
7.2. |
Podophyllotoxin and Its Derivatives |
7.3. |
Camptothecin and Analogs |
7.4. |
Taxoids |
7.5. |
Epothilone A and B |
8. |
Heavy-Metal Complexes |
8.1. |
cis-Platinum |
8.1.1. |
Mechanism of Action |
8.1.2. |
Mechanisms of Resistance |
8.2. |
Carboplatin |
8.3. |
Analogs |
9. |
Hormonally Active Anticancer Drugs/Antihormones |
9.1. |
Antiestrogens |
9.1.1. |
Antagonists |
9.1.2. |
Tamoxifen, Toremifene |
9.1.3. |
Analogs |
9.2. |
Aromatase Inhibitors |
9.3. |
Antiandrogens |
9.3.1. |
Flutamide |
9.3.2. |
Nilutamide |
9.3.3. |
Bicalutamide |
9.4. |
LHRH Analogs |
9.4.1. |
LHRH Agonists |
9.4.1.1. |
Leuprorelin Acetate |
9.4.1.2. |
Goserelin |
9.4.2. |
LHRH Antagonists |
9.4.2.1. |
Receptor Assays |
9.4.2.2. |
Peptidomimetics |
10. |
Signal Transduction Inhibitors |
10.1. |
Enzyme Inhibitors |
10.2. |
Phospholipid - Based Antineoplastics |
11. |
Economic Aspects |
References
- 1 I. B. Weinstein, Cancer Res. (Suppl.) 51 (1991) 5080.
- 2
R. Doll,
Eur. J. Cancer
26
(1990)
5007.
10.1016/0277-5379(90)90025-O Google Scholar
- 3 C. LaVecchina, F. Levi, F. Lucchini, S. Garattini, Anti-Cancer-Drugs 2 (1991) 215.
- 4 D. Kessel, In Vivo 8 (1994) 829.
- 5 T. Tsurno, A. Toninda, Anti-Cancer-Drugs 6 (1995) 213.
- 6 G. Eisenbrand, S. Lauch-Birkel, W. C. Tang, Synthesis (1996) 1246.
- 7 G. B. Elion, Cancer Res. 45 (1985) 2943.
- 8 Scrip 1997, July 15, p. 20.
- 9 Chem. Marketing Report, July 14, 1997, p. 19.
- 10 Med. Ad-News, May 1996, p. 56.
- 11 G. M. Cragg, D. J. Newman, K. M. Snader, J. Nat. Prod. 60 (1997) 52 – 60.
- 12 K. Nasmyth, Science 274 (1996) 1643 – 1645.
- 13 G. Dratta, H. Pagano, Annu. Rep. Med. Chem. 31 (1996) 241 – 248.
- 14 Pharma Business, July/August 1997, p. 62.
- 15 S. A. Rosenberg: “Principles of Surgical Oncology,” in V. T. DeVita, S. Hellman, S. A. Rosenberg (eds.): Cancer: Principles and Practice of Oncology, J. B. Lippincott Co., Philadelphia 1982, pp. 93 – 102.
- 16 S. Farber, L. K. Diamond, R. D. Mercer, R. F. Sylvester, V. A. Wolff, N. Engl. J. Med. 238 (1948) 787 – 793.
- 17 R. Hertz, G. T. Ross, M. B. Lipsett, Am. J. Obstet. Gynecol. 86 (1963) 808 – 814.
- 18 R. L. Kisliuk, Y. Gaumont, C. M. Baugh, J. M. Galivan, G. F. Maley, F. Maley: “Inhibition of Thymidylate Synthetase by Poly-gamma-glutamyl Derivatives of Folate and Methotrexate,” in R. L. Kisliuk, G. M. Brown (eds.): Chemistry and Biology of the Pteridines, Elsevier/North Holland, New York 1979, pp. 431 – 435.
- 19 I. D. Goldman, N. S. Lichtenstein, V. T. Oliverio, J. Biol. Chem. 243 (1968) 5007 – 5017.
- 20 F. M. Sirotnak, R. C. Donsbach, Cancer Res. 36 (1976) 1151 – 1158.
- 21 R. D. Warren, A. P. Nichols, R. A. Bender, Cancer Res. 38 (1978) 668 – 671.
- 22 P. L. Chello, F. M. Sirotnak, D. M. Dorck et al., Cancer Res. 37 (1977) 4297 – 4303.
- 23 B. T. Hill, B. D. Bailey, J. C. White et al., Cancer Res. 39 (1979) 2440 – 2446.
- 24 F. M. Sirotnak, R. C. Donsbach, Cancer Res. 35 (1975) 1737 – 1744.
- 25 J. J. McGuire, J. R. Bertino, Mol. Cell Biochem. 38 (1981) 19 – 48.
- 26 R. L. Schilsky, B. D. Bailey, B. A. Chabner, Proc. Natl. Acad. Sci. USA 77 (1980) 2919.
- 27 S. A. Jacobs, C. J. Derr, D. G. Johns, Biochem. Pharmacol. 26 (1977) 2310 – 2313.
- 28 V. M. Whitehead, Cancer Res. 37 (1977) 408 – 412.
- 29 J. Jolivet, B. A. Chabner, J. Clin. Invest. 72 (1983) 773 – 778.
- 30 S. V. Gupta, N. J. Greenfield, M. Poe et al., Biochemistry 16 (1977) 3073 – 3079.
- 31 H. Nakamura, J. Littlefield, J. Biol. Chem. 247 (1972) 179 – 187.
- 32 D. A. Matthews, R. A. Alden, J. T. Bolin et al.:“X-ray Structural Studies of Dihydrofolate Reductase,” in R. L. Kisliuk, G. M. Brown (eds.): Chemistry and Biology of the Pteridines, Elsevier/North Holland, New York 1979, pp. 465 – 470.
- 33 P. A. Charlton, D. W. Young, B. Birdsall et al., Chem. Commun. 20 (1979) 922 – 924.
- 34 D. A. Matthews, R. A. Alden, J. T. Bolin et al., Science 197 (1977) 452 – 455.
- 35 W. L. Werkheiser, Cancer Res. 23 (1963) 1277 – 1285.
- 36 B. A. Kamen, W. Whyte-Bauer, J. R. Bertino, Biochem. Pharmacol. 32 (1983) 1837 – 1841.
- 37 R. J. Kaufman, J. R. Bertino, R. T. Schimke, J. Biol. Chem. 253 (1978) 5852 – 5860.
- 38 E. W. Alt, R. E. Kellems, J. R. Bertino et al., J. Biol. Chem. 253 (1978) 1357.
- 39 G. A. Curt, J. Jolivet, B. D. Bailey, D. N. Carney, B. A. Chabner, Biochem. Pharmacol. 33 (1984) 1682 – 1685.
- 40 G. A. Curt, D. N. Carney, K. H. Cowan, J. Jolivet et al., N. Engl. J. Med. 308 (1982) 199.
- 41 M. J. Cline, H. Stang, K. Mercola et al., Nature (London) 284 (1980) 922 – 925.
- 42 M. Bar-Eli, H. D. Stang, K. E. Mercola, M. J. Cline, Somatic Cell Genet. 9 (1983) 55 – 67.
- 43 F. Carr, W. D. Medina, S. Dube, J. R. Bertino, Blood 62 (1983) 180 – 185.
- 44 H. Diddens, D. Niethammer, R. C. Jackson, Cancer Res. 43 (1983) 5286 – 5292.
- 45 F. M. Sirotnak, J. I. Degraw, F. A. Schmid, L. J. Goutas et al., Cancer Chemother. Pharmacol. 12 (1984) 26 – 30.
- 46 R. P. Hertzberg, R. K. Johnson, Annu. Rep. Med. Chem. 28 (1993) 167 – 176.
- 47 G. F. Fleming, R. L. Schilsky, Semin. Oncol. 19 (1992) 707.
- 48 K. Y. Shum et al., J. Clin. Oncol. 6 (1988) 446.
- 49 A. L. Lackman et al., Cancer Res. 51 (1991) 5579.
- 50 D. Cunningham, Cancer Res. 53 (1991) 810.
- 51 A. L. Jackman, D. C. Farrugia, W. Gibson, Eur. J. Cancer 13A (1995) 1277 – 1282.
- 52 M. D. Varney et al., J. Med. Chem. 35 (1992) 663.
- 53 C. Heidelberger, N. K. Chandhavi, P. Dannenberg et al., Nature (London) 179 (1957) 663 – 666.
- 54 R. J. Rutman, A. Cantarow, K. E. Paschkis, Cancer Res. 14 (1954) 119 – 126.
- 55 R. L. Glazer, L. S. Lloyd, Molec. Pharmacol. 21 (1982) 468 – 473.
- 56 D. W. Kufe, P. P. Major, J. Biol. Chem. 256 (1981) 9802 – 9806.
- 57 K. V. Hadjiolova, Z. G. Naydenova, A. A. Hadjiolova, Biochem. Pharmacol. 30 (1981) 1861 – 1866.
- 58 R. I. Glazer, K. D. Hartman, Molec. Pharmacol. 23 (1983) 540 – 546.
- 59 Y. Oshima, M. Itoh, N. Okada, T. Miyata, Proc. Natl. Acad. Sci. USA 78 (1981) 4471 – 4474.
- 60 D. W. Kufe, P. P. Major, E. M. Egan, E. Leh, J. Biol. Chem. 256 (1981) 8885 – 8889.
- 61 P. V. Danenberg, C. Heidelberger, M. A. Mulkins, A. R. Peterson, Biochem. Biophys. Res. Commun. 102 (1981) 654 – 659.
- 62 Y. C. Cheng, K. Nakayama, Molec. Pharmacol. 23 (1983) 171 – 174.
- 63 M. Tanaka, K. Kimura, S. Yoshida, Cancer Res. 43 (1983) 5145 – 5150.
- 64 P. Reichard, O. Skold, G. Klein et al., Cancer Res. 22 (1962) 235 – 243.
- 65 P. Reyes, T. C. Hall, Biochem. Pharmacol. 18 (1969) 1587 – 1590.
- 66 D. K. Kasbeker, D. M. Greenberg, Cancer Res. 23 (1963) 818 – 825.
- 67 P. Reichard, O. Skold, G. Klein, Nature (London) 183 (1959) 939 – 941.
- 68 J. A. Houghton, S. J. Masada, J. O. Phillips et al., Cancer Res. 42 (1982) 144 – 149.
- 69 C. Heidelberger, G. Kaldos, K. L. Mukherjee et al., Cancer Res. 20 (1960) 903 – 909.
- 70 M. M. Lastieboff, B. Kedzioska, W. Rode, Biochem. Pharmacol. 32 (1983) 2259 – 2267.
- 71 A. R. Bapat, C. Zarow, P. V. Dannenberg, J. Biol. Chem. 258 (1983) 4130 – 4136.
- 72 C. C. Rossana, L. G. Rao, L. F. Johnson, Mol. Cell. Biol. 2 (1982) 1118 – 1125.
- 73 F. Baskin, S. C. Carlin, P. Kraus et al., Molec. Pharmacol. 11 (1975) 105 – 117.
- 74 D. G. Priest, B. E. Ledford, M. T. Doig, Biochem. Pharmacol. 29 (1980) 1549 – 1553.
- 75 R. D. Armstrong, E. Cadman, Cancer Res. 43 (1983) 2525 – 2528.
- 76 J. L. Au, Y. M. Rustum, J. Minonda, B. I. Sriva-stava, Biochem. Pharmacol. 32 (1983) 541 – 545.
- 77 Y. M. El Sayed, W. Sadee, Cancer Res. 43 (1983) 4039 – 4044.
- 78 E. J. Ansfield, G. J. Kallas, J. P. Simpson, J. Clin. Oncol. 1 (1983) 107 – 110.
- 79 F. Sorm, A. Piskala, A. Cihak et al., Experientia 20 (1964) 202 – 203.
- 80 A. Piskala, F. Sorm, Collect. Czech. Chem. Commun. 29 (1964) 2060 – 2075.
- 81 P. G. W. Plagemann, M. Behrens, D. Abraham, Cancer Res. 38 (1978) 2458 – 2466.
- 82 J. C. Drake, R. G. Stoller, B. A. Chabner, Biochem. Pharmacol. 26 (1977) 64 – 66.
- 83 T. Lee, M. Karon, R. L. Momparler, Cancer Res. 34 (1974) 2481 – 2488.
- 84 A. Cihak, Collect. Czech. Chem. Commun. 39 (1974) 3782 – 3792.
- 85 J. Doskel, V. Paces, F. Sorm, Biochim. Biophys. Acta 145 (1967) 771 – 779.
- 86 L. H. Li, E. J. Olin, T. J. Fraser et al., Cancer Res. 30 (1970) 2770 – 2775.
- 87 B. F. Vanyosbin, S. G. Tkacheug, A. W. Belozinsky, Nature (London) 225 (1976) 948 – 949.
- 88 J. L. Mandell, P. Chambon, Nucleic Acids Res. 7 (1979) 2081 – 2103.
- 89 J. D. McGhee, G. D. Gineler, Nature (London) 280 (1979) 419 – 420.
- 90 C. Scheir, T. Maniatis, Proc. Natl. Acad. Sci. USA 77 (1980) 6634 – 6638.
- 91 L. H. Van der Ploeg, R. A. Flavill, Cell 19 (1980) 947 – 958.
- 92 O. Niwa, T. Sugarhar, Proc. Natl. Acad. Sci. USA 78 (1981) 6290 – 6294.
- 93 S. Friedman, Molec. Pharmacol. 19 (1980) 314 – 320.
- 94 D. V. Santi, C. E. Garrett, P. J. Barr, Cell 25 (1983) 9 – 10.
- 95 P. G. Constantinides, P. A. Jones, W. Geness, Nature (London) 267 (1977) 364 – 366.
- 96 P. A. Jones, S. M. Taylor, Cell 20 (1980) 85 – 93.
- 97 T. J. Ley, J. DeSimone, N. P. Anagnov et al., N. Engl. J. Med. 307 (1982) 1469 – 1475.
- 98 J. Vesely, A. Chiak, Pharmacol. Therap. 2 (1978) 813 – 840.
- 99 T. Lee, M. R. Kovan, Biochem. Pharmacol. 25 (1976) 1737 – 1742.
- 100 A. Cihak, H. Vessela, F. Sorm, Biochem. Biophys. Acta 166 (1968) 277 – 279.
- 101 A. Cihak, J. Vesely, Biochem. Pharmacol. 21 (1972) 3257 – 3265.
- 102 J. Vesely, A. Cihak, F. Sorm, Int. J. Cancer 2 (1967) 639 – 646.
- 103 J. Doskacil, F. Sorm, FEBS Lett. 2 (1974) 30 – 32.
- 104 D. D. Von Hoff, M. Slavik, F. M. Muggia, Ann. Intern. Med. 85 (1976) 237 – 245.
- 105 Z. H. Israili, W. R. Vogler, E. S. Mingidi et al., Cancer Res. 36 (1971) 1453 – 2461.
- 106 J. A. Beisler, J. Mol. Chem. 21 (1978) 204 – 208.
- 107 J. A. Beisler, M. M. Abbasi, J. S. Driscoll, Cancer Treat. Rep. 60 (1976) 1671 – 1674.
- 108 G. A. Curt, J. A. Kelley, R. L. Fine et al., Proc. Am. Assoc. Clin. Oncol. 3 (1984) 37.
- 109 P. G. W. Plagemann, R. Marz, R. M. Wolhvete, Cancer Res. 38 (1978) 978 – 989.
- 110 A. Iwagaki, T. Nakamura, G. Wakisaka, Cancer Res. 29 (1969) 2169 – 2176.
- 111 M. Y. Chu, G. A. Fisher, Biochem. Pharmacol. 11 (1962) 423 – 430.
- 112 P. P. Major, E. M. Egan, G. P. Beardsley, M. D. Minden et al., Proc. Natl. Acad. Sci. USA 78 (1983) 3235 – 3239.
- 113 P. P. Major, L. Sargent, E. M. Egan, D. W. Kufe, Biochem. Pharmacol. 30 (1981) 2221 – 2224.
- 114 P. P. Major, E. M. Egan, D. Herrick, D. W. Kufe, Biochem. Pharmacol. 31 (1982) 861 – 866.
- 115 M. Y. Chu, G. A. Fisher, Biochem. Pharmacol. 14 (1965) 333 – 341.
- 116 M. R. Atkinson, M. Deutscher, A. Kornberg, A. Russel et al., Biochemistry 8 (1969) 4897 – 4904.
- 117 P. A. Diskwel, F. Wanka, Biochim. Biophys. Acta 520 (1978) 461 – 471.
- 118 R. J. Frann, C. M. Egan, D. W. Kufe, Leuk. Res. 7 (1983) 243 – 249.
- 119 J. F. Ward, E. I. Jones, W. F. Blakely, Cancer Res. 44 (1984) 59 – 63.
- 120 S. R. Bähring-Kuhlmey, Drugs of Today 13 (1977) 475.
- 121 A. A. Claesen et al., Tetrahedron Lett. (1966) 3499.
- 122 P. Major et al., Proc. Natl. Acad. Sci. USA 78 (1981) 3235.
- 123 R. Preston, Treat. Carcinogen Mutagen 1 (1980) 147.
- 124 P. Drahovsky, W. Kreis, Biochem. Pharmacol. 19 (1970) 940 – 944.
- 125 W. Kreis, J. Graham, L. A. Damin, Biochem. Pharmacol. 31 (1982) 3831 – 3837.
- 126 J. Balzarini, E. De Cleireg, Mol. Pharmacol. 23 (1983) 175 – 181.
- 127 A. W. Harris, E. C. Reynolds, L. R. Finch, Cancer Res. 39 (1979) 538 – 541.
- 128 Y. Rustum, H. Priesler, Cancer Res. 39 (1979) 42 – 49.
- 129 C. D. Stuart, P. J. Burke, Nat. New Biol. 233 (1971) 109 – 110.
- 130 P. Chang, P. H. Wiernik, S. D. Reich et al.: “Prediction of Response to Cytosine Arabinoside and Daunorubicin in Acute Nonlymphocytic Leukemia,” in F. Mandelli (ed.): Therapy of Acute Leukemias, Lombardo-Editore, Rome 1977, pp. 148 – 159.
- 131 J. F. Smyth, A. B. Robins, C. L. Leese, Eur. J. Cancer 12 (1976) 567 – 573.
- 132 M. N. H. Tattersall, U. K. Ganeshaguru, A. V. Hoffbrand, Br. J. Haematol. 27 (1974) 39 – 46.
- 133 M. Aoshima et al., Cancer Res. 37 (1977) 1481.
- 134
F. Cabaninas,
Drugs of the Future
5
(1980)
12,
603.
10.1358/dof.1980.005.12.312115 Google Scholar
- 135 T. Ueda, T. Nakamura, S. Ando et al., Cancer Res. 43 (1983) 3412 – 3416.
- 136 K. Hoie, T. Tsuro, K. Naganuma, S. Tsukagoshi et al., Cancer Res. 44 (1984) 172 – 177.
- 137 C. W. Young, R. Schneider, B. Leyland-Jones et al., Cancer Res. 43 (1983) 5006 – 5009.
- 138 Y. C. Cheng, R. S. Tan, J. L. Ruth, G. Dutschman, Biochem. Pharmacol. 32 (1983) 726 – 729.
- 139 L. W. Hertel, J. S. Kroin, J. W. Misner, J. M. Tustin, J. Org. Chem. 53 (1988) 11, 2406 – 2409.
- 140 Eli Lilly, EP 122707 ,1984 (L. W. Hertel).
- 141 Eli Lilly, EP 184365 ,1986 (G. B. Grindey, L. W. Hertel).
- 142 Eli Lilly, EP 306190 ,1989 T. S. Chou, P. Heath). L. E. Patterson).
- 143 S. Chubb et al., Proc. Am. Assoc. Cancer Res. 28 (1987) Abst. 1282.
- 144 D. Y. Bouffard, L. F. Momparler, R. L. Momparler, Eur. J. Pharmacol. 183 (1990) 2, Abst. 032.
- 145 V. Heinemann, L. W. Hertel, G. B. Grindley, W. Phukett, Cancer Res. 48 (1988) 14, 4024 – 4031.
- 146
M. N. Serradel,
J. Castañer,
Drugs of the Future
15
(1990)
8,
794 – 797.
10.1358/dof.1990.015.08.118991 Google Scholar
- 147 V. Heinemann et al., Proc. Am. Assoc. Cancer Res. 30 (1989) Abst 2204.
- 148 H. H. Hansen, Ann. Oncol. 120 (1994) 519 – 528.
- 149 E. Beutler, Lancet 340 (1992) 8825, 952.
- 150 H. M. Bryson, E. M. Sorkin, Drugs 46 (1993) 5, 872.
- 151 E. H. Estey et al., Blood 79 (1992) 4, 882.
- 152 S. P. Smith, Hosp. Formul. 28 (1993) 7, 621.
- 153
C. P. Robinson,
Drugs Today
29
(1993)
6,
379.
10.1358/dot.1993.29.6.240453 Google Scholar
- 154 US 4357324, 1982 (J. A. Montgomery, A. T. Shortnacy).
- 155 R. W. Brockman, Y. C. Cheng, F. M. Schabel, J. M. Montgomery, Cancer Res. 40 (1980) 3610 – 3615.
- 156 J. A. Montgomery, Cancer Res. 42 (1982) 3911 – 3917.
- 157 W. C. Tseng et al., Mol. Pharmacol. 21 (1982) 474 – 477.
- 158
S. J. Hopkins,
Drugs of the Future
10
(1985)
1,
20.
10.1358/dof.1985.010.01.62053 Google Scholar
- 159 Annu. Drug Data Rep. (1992) 633 – 634.
- 160 J. S. Whelan et al., Brit. J. Cancer 64 (1991) 1, 120.
- 161 H. S. Hochster et al., J. Clin. Oncol. 10 (1992) 1, 28.
- 162 H. W. Dion et al., Ann. NY Acad. Sci. 284 (1977) 21 – 29.
- 163 Parke Davis, US 3923785, 1975 (A. Ryder et al.).
- 164 P. W. Woo et al., J. Heterocycl. Chem. 11 (1974) 4, 641 – 643.
- 165 J. F. Smith et al., Cancer Chemother. Pharmacol. 1 (1978) 49 – 51.
- 166 J. F. Smith et al., Proc. Am. Assoc. Cancer Res. 20 (1979) .
- 167 G. A. Le Page et al., Cancer Res. 36 (1976) 1481 – 1485.
- 168
M. N. Seradel,
J. Castañer,
Drugs of the Future
6
(1981)
419 – 420.
10.1358/dof.1981.006.07.66419 Google Scholar
- 169 M. Blick et al., Am. J. Hematol. 33 (1990) 3, 205 – 209.
- 170 S. Bernhard et al., Med. Pediatr. Oncol. 19 (1991) 4, 276.
- 171 A. D. Ho et al., J. Natl. Canver Inst. 82 (1990) 17, 1416 – 1420.
- 172 E. H. Kraut et al., J. Clin. Oncol. 7 (1989) 2, 168 – 172.
- 173 R. S. Witte et al., Invest. New Drug 10 (1992) 1, 49.
- 174 B. J. Kane, J. G. Kuhn, M. K. Roush, Ann. Pharmacother. 26 (1992) 939 – 947.
- 175 G. B. Elion, E. Burgi, G. H. Hitchings, J. Am. Chem. Soc. 74 (1952) 411.
- 176 G. B. Elion, G. H. Hitchings, J. Am. Chem. Soc. 77 (1955) 1676.
- 177 J. H. Burchenal, M. L. Murphy, R. R. Ellison et al., Blood 8 (1953) 965.
- 178 G. H. Hitchings, G. B. Elion, Ann. N.Y. Acad. Sci. 60 (1954) 195.
- 179 R. W. Brockman, C. S. Debavadi, P. Stutts, D. J. Hutchison, J. Biol. Chem. 236 (1961) 1471 – 1479.
- 180 J. D. Davidson, Cancer Res. 20 (1960) 225 – 232.
- 181 G. B. Elion, Fed. Proc. 26 (1967) 898 – 904.
- 182 J. F. Henderson, M. K. Y. Khoo, J. Biol. Chem. 240 (1965) 2349 – 2357.
- 183 F. F. Snyder, J. F. Henderson, Can. J. Biochem. 51 (1973) 943 – 948.
- 184 P. C. L. Wong, J. F. Henderson, Biochem. J. 129 (1972) 1085 – 1094.
- 185 T. Fields, L. Brox, Can. J. Biochem. 52 (1974) 441 – 446.
- 186 C. D. Green, D. W. Martin Jr., Proc. Natl. Acad. Sci. USA 70 (1973) 3698 – 3702.
- 187 G. B. Elion, S. Callahan, W. Rundles, G. H. Hitchings, Cancer Res. 23 (1963) 1207 – 1217.
- 188 G. H. Hitchings, Cancer Res. 23 (1963) 1218 – 1225.
- 189 T. Nakamura, Blood & Vessel (Jpn.) 2 (1971) 237 – 248.
- 190 T. Higuchi, T. Nakamura, G. Wakisaka, Blood &Vessel (Jpn.) 3 (1972) 313 – 318.
- 191 P. W. Allan, L. L. Bennett Jr., Biochem. Pharmacol. 20 (1971) 847 – 852.
- 192 A. Hampton, J. Biol. Chem. 238 (1963) 3068 – 3074.
- 193 R. J. McCollister, W. R. Gilbert, D. M. Ashton, J. B. Wyngaarden, J. Biol. Chem. 239 (1964) 1560 – 1563.
- 194 R. P. Miech, R. E. Parks Jr., J. H. Anderson Jr., A. C. Sartorelli, Biochem. Pharmacol. 16 (1967) 2222 – 2227.
- 195 A. R. P. Paterson, D. M. Tidd: “6-Thiopurines,” in A. C. Sartorelli, D. G. Johns (eds.): Handbook of Experimental Pharmacology, vol. 38, Springer-Verlag, Berlin 1975, Part 2, pp. 384 – 403.
- 196 D. L. Hill, L. L. Bennett Jr., Biochemistry 8 (1969) 122.
- 197 R. T. Kavahata, L. F. Chuang, C. A. Holmberg, B. I. Osburn et al., Cancer Res. 43 (1983) 3655 – 3659.
- 198 J. Maybaum, H. G. Mandel, Cancer Res. 43 (1983) 3852 – 3856.
- 199 J. S. Lazo, K. M. Huang, A. C. Sartorelli, Cancer Res. 37 (1977) 4250.
- 200 C. K. Carrico, A. C. Sartorelli, Cancer Res. 37 (1977) 1868.
- 201 K. Kim, W. J. Blechman, V. G. H. Riddle, A. B. Pardee, Cancer Res. 41 (1981) 4529.
- 202 J. D. Strobel-Stevens, S. M. El Dareer, M. W. Trader, D. L. Hill, Biochem. Pharmacol. 31 (1982) 3133.
- 203 M. Rosman, H. E. Williams, Cancer Res. 33 (1973) 1202.
- 204 M. K. Wolpert, S. P. Damle, J. E. Brown et al., Cancer Res. 31 (1971) 1620.
- 205 M. Rosman, M. L. Lee, W. A. Creasey et al., Cancer Res. 34 (1974) 1952.
- 206 E. M. Scholar, P. Calabresi, Biochem. Pharmacol. 28 (1979) 445.
- 207 L. Tterlikkis, J. L. Day, D. A. Brown, E. C. Schroeder, Cancer Res. 43 (1983) 1675 – 1679.
- 208 S. Zimm, J. M. Collins, D. O'Neill, B. A. Chabner et al., Clin. Pharmacol. Therap. 34 (1983) 810 – 817.
- 209 S. Zimm, J. M. Collins, R. Riccardi, D. O'Neill et al., N. Engl. J. Med. 308 (1983) 1005 – 1009.
- 210 R. D. Armstrong, R. Vera, P. Snyder, E. Cadman, Biochem. Biophys. Res. Commun. 109 (1982) 595.
- 211 M. Inomata, F. Fukuoka, A. Hoshi, K. Kuretani et al., J. Pharmacobiodyn. 4 (1981) 928.
- 212 D. M. Tidd, I. Gibson, P. D. G. Dean, Cancer Res. 42 (1982) 3769.
- 213 M. Inaba, M. Fukui, N. Yoshida, S. Tsukagoshi et al., Cancer Res. 42 (1982) 1103.
- 214 C. P. J. Adair, H. J. Bragg, Ann. Surg. 93 (1931) 190.
- 215 L. P. Jacobson, C. L. Spurr, E. S. O. Barron et al., J. Am. Med. Assoc. 132 (1946) 126.
- 216 M. Colvin: “The Alkylating Agents,” in B. A. Chabner (ed.): Pharmacologic Principles of Cancer Treatment, W. B. Saunders, Philadelphia 1982, pp. 276 – 308.
- 217 N. O. Goldstein, R. J. Rutman, Cancer Res. 24 (1964) 1363.
- 218 R. W. Ruddon, J. M. Johnson, Mol. Pharmacol. 4 (1968) 258.
- 219 G. P. Wheeler, J. A. Alexander, Cancer Res. 29 (1969) 98.
- 220
P. Brookes,
P. D. Lawley,
Biochem. J.
80
(1961)
486.
10.1042/bj0800496 Google Scholar
- 221 C. C. Price, G. M. Gaucher, P. Koneru et al., Biochim. Biophys. Acta 166 (1968) 327.
- 222 A. Loveless, W. C. J. Ross, Nature (London) 166 (1950) 1113.
- 223 K. W. Kohn, L. C. Erickson, R. A. G. Ewig et al., Biochemistry 15 (1976) 4629.
- 224 R. J. Rutman, E. H. C. Chun, F. A. Lewis, Biochem. Biophys. Res. Commun. 32 (1968) 650.
- 225 I. Hirono, Nature (London) 186 (1960) 1059.
- 226 G. Calcutt, T. A. Connors, Biochem. Pharmacol. 12 (1963) 839.
- 227 R. A. G. Ewig, K. W. Kohn, Cancer Res. 37 (1977) 2114.
- 228 L. C. Ericson, G. Laurent, N. A. Sharkey et al., Nature (London) 288 (1980) 727 – 729.
- 229 D. T. Vistica, J. N. Toal, M. Rabinowitz, Biochem. Pharmacol. 27 (1978) 2865.
- 230 W. R. Redwood, M. Colvin, Cancer Res. 40 (1980) 1144.
- 231 W. P. Brade, J. Engel, Drugs Today 20 (1984) 491 – 496.
- 232 P. J. Creaven, L. M. Allen, D. A. Alford et al., Clin. Pharmacol. Therap. 16 (1974) 77.
- 233 T. A. Conners: “Alkylating Agents, Nitrosourea, and Alkyltriazines,” in H. M. Pinedo, B. A. Chabner (eds.): Cancer Chemotherapy Annual 5, Elsevier, Amsterdam 1983, pp. 30 – 65.
- 234 A. Mittelman et al., J. Urol. (Baltimore) 115 (1976) 409.
- 235 W. A. Skinner, H. F. Gram, M. O. Green et al., J. Med. Pharmaceut. Chem. 2 (1960) 299.
- 236 K. A. Hyde, E. Acton, W. A. Skinner et al., J. Med. Pharmaceut. Chem. 5 (1962) 1.
- 237 F. M. Schabel, T. P. Johnston, G. S. McGaleb et al., Cancer Res. 23 (1963) 226.
- 238 K. W. Kohn, Cancer Res. 37 (1977) 1450.
- 239 R. J. Weinkam, D. F. Deen, Cancer Res. 42 (1982) 1008.
- 240 J. Mendel, R. Thust, H. Schwartz, Arch. Geschwulstforsch. 52 (1982) 371.
- 241 B. J. Bowdon, J. Grimsley, H. H. Lloyd, Cancer Res. 34 (1974) 194.
- 242 L. C. Panasci, D. Green, R. Nagourney et al., Cancer Res. 37 (1977) 2615.
- 243 J. M. Dornish, I. Smith-Kielland, FEBS Lett. 139 (1981) 41.
- 244 K. D. Tew, A. L. Wang, Molec. Pharmacol. 21 (1982) 729.
- 245 A. Begleiter, H. Y. P. Lam, G. J. Goldenberg, Cancer Res. 37 (1977) 1022.
- 246 N. G. Goldstein, R. J. Rutman, Cancer Res. 24 (1964) 1363.
- 247 R. W. Ruddon, J. M. Johnson, Molec. Pharmacol. 4 (1968) 258.
- 248 J. J. Roberts, T. P. Brent, A. R. Crathorn, Eur. J. Cancer 7 (1971) 515.
- 249 W. P. Tong, D. B. Ludlam, Biochim. Biophys. Acta 608 (1980) 174.
- 250 C. C. Price, G. M. Gaucher, P. Koneru et al., Biochim. Biophys. Acta 166 (1968) 327.
- 251
P. Brookes,
P. D. Lawley,
Biochem. J.
80
(1961)
486.
10.1042/bj0800496 Google Scholar
- 252 C. B. Thomas, R. Osieka, K. W. Kohn, Cancer Res. 38 (1978) 2448.
- 253 C. C. Erickson, M. O. Bradley, S. M. Ducore et al., Proc. Natl. Acad. Sci. USA 77 (1980) 467.
- 254 R. A. G. Ewig, K. W. Kohn, Cancer Res. 38 (1978) 3197.
- 255 W. G. Verly, Y. Paquette, Cancer J. Biochem. 50 (1972) 217.
- 256 L. C. Ericson, G. Laurent, N. A. Sharkey et al., Nature (London) 288 (1980) 727 – 729.
- 257 A. R. Crathorne, J. J. Roberts, Nature (London) 211 (1966) 150.
- 258 K. Tsujihara, M. Ozeki, T. Morikawa, M. Kawamori et al., J. Med. Chem. 25 (1982) 441.
- 259 Y. Akaike, Y. Arai, H. Takuchi, H. Satoh, Gann 73 (1982) 480.
- 260 W. J. Zeller, M. Berger, G. Eisenbrand, W. Tang et al., Arzneim.-Forsch. 32 (1982) 484.
- 261 J. R. Prous, Drug News Perspect 1 (1988) 1, 35.
- 262 ADIR, FR 2536075 ,1984 (C. Cudennec, G. Lavielle).
- 263
M. N. Serradel,
J. Castañer,
Drugs of the Future
14
(1989)
11,
1042 – 1046.
10.1358/dof.1989.014.11.109641 Google Scholar
- 264 S. Filippeschi et al., Anticancer Res. 14 (1988) 11, 1351 – 1354.
- 265 D. Khayat et al., Cancer Res. 47 (1987) 6782 – 6785.
- 266 J. A. Boutin et al., Eur. Cancer Oncol. (1989) .
- 267 P. Deloffre, C. A. Cudennec, G. Lavielle, J. P. Bizzari, 15th Int. Cong. Chemother., Istanbul 1987, Abst. 755.
- 268 J. Jacquillat et al., Proc. Am. Assoc. Cancer Res. 30 (1989) Abst. 1088.
- 269 P. Zeller, H. Gutmann, B. Hegedus et al., Experientia 19 (1963) 129.
- 270
V. T. DeVita,
A. Serpick,
P. Carbone,
Ann. Intern. Med.
73
(1970)
542.
10.7326/0003-4819-73-6-881 Google Scholar
- 271
J. Gutterman,
A. Huang,
P. Hochstein,
Proc. Soc. Exp. Biol. Med.
130
(1979)
797.
10.3181/00379727-130-33658 Google Scholar
- 272 R. J. Weinkam, D. A. Shiba, Life Sci. 22 (1978) 937.
- 273 D. L. Dunn, R. A. Lubet, R. A. Prough, Cancer Res. 39 (1979) 4555.
- 274 D. E. Schwartz, W. Bollag, P. Obrecht, Arzneim.- Forsch. 17 (1967) 1389.
- 275 D. Reed, F. Dost, Proc. Am. Assoc. Cancer Res. 7 (1965) 57.
- 276 M. Baggiolini, B. Dewald, H. Aebi, Biochem. Pharmacol. 18 (1969) 2187.
- 277 C. Pueyo, Mutat. Res. 67 (1979) 189.
- 278 E. Therman, Cancer Res. 32 (1972) 1111.
- 279 W. Kreis, Proc. Am. Assoc. Cancer Res. 7 (1966) 39.
- 280 A. Sartorelli, S. Tsunamura, Proc. Am. Assoc. Cancer Res. 6 (1965) 55.
- 281 H. Lam, A. Begleiter, W. Stein et al., Biochem. Pharmacol. 27 (1978) 1883.
- 282 J. L. Skibba, D. D. Beal, G. Ramirez et al., Cancer Res. 30 (1970) 147.
- 283 P. Farina, A. Gescher, J. A. Hickman, J. K. Horton et al., Biochem. Pharmacol. 31 (1982) 1887.
- 284 T. L. Loo, G. E. Housholder, A. H. Gerulath et al., Cancer Treat. Rep. 60 (1976) 149.
- 285 D. D. Beal, J. L. Skibba, K. K. Whitnable et al., Cancer Res. 36 (1976) 2827.
- 286 A. H. Gerulath, T. L. Loo, Biochem. Pharmacol. 21 (1972) 2335.
- 287 D. W. Kaiser, I. T. Thurston, J. R. Dudley et al., J. Am. Chem. Soc. 73 (1951) 2984.
- 288 J. F. Worzalla, B. D. Kaima, B. M. Johnson et al., Cancer Res. 34 (1974) 2669.
- 289 J. F. Worzalla, B. D. Kaima, B. M. Johnson et al., Cancer Res. 33 (1973) 2810.
- 290 B. C. V. Mitchley, S. A. Clarke, T. A. Connors et al., Cancer Treat. Rep. 61 (1977) 3.
- 291 M. Ames, G. Powis, J. S. Kovach et al., Cancer Res. 39 (1979) 5016.
- 292 L. M. Lake, E. E. Grunden, B. M. Johnson, Cancer Res. 35 (1975) 2858.
- 293 A. J. Cumber, W. C. J. Ross, Chem. Biol. Interact. 17 (1977) 349.
- 294 V. Iver, W. Szybalski, Science (Washington) 145 (1964) 55 – 58.
- 295 L. Littlefield et al., Mut. Res. 81 (1981) 377.
- 296 J. Mac Donald et al., Ann. Intern. Med. 93 (1980) 533.
- 297 Drugs Today 20 (1984) 489; 21 (1985) 420.
- 298
Drugs of the Future
8
(1983)
402;
9
(1984)
371;
10
(1985)
420.
10.1358/dof.1983.008.05.199331 Google Scholar
- 299 F. Arcamone et al., J. Med. Chem. 18 (1975) 703.
- 300 Microbiochem. Res. Found., US 4303785 (H. Naganawa, T. Takenchi, H. Umezawa).
- 301 H. Umezawa et al., J. Antibiot. 32 (1979) 1082 – 1085.
- 302
M. N. Serradel,
J. Castañer,
Drugs of the Future
8
(1983)
7,
610 – 611.
10.1358/dof.1983.008.07.64379 Google Scholar
- 303 T. Nishimura et al., J. Antibiot. 33 (1980) 737 – 743.
- 304 D. Dantchev et al., J. Antibiot. 32 (1979) 1085 – 1086.
- 305 H. Brockmann, Fortschr. Chem. Org. Naturst. 50 (1973) 121.
- 306 C. E. Myers: “Anthracyclines,” in B. A. Chabner (ed.): Pharmacologic Principles of Cancer Treatment, W. B. Saunders, Philadelphia 1982, pp. 416 –434.
- 307 R. Phillips, A. DiMarco, F. Zunino, Eur. J. Biochem. 85 (1978) 487.
- 308 R. B. Painter, Cancer Res. 38 (1978) 4445.
- 309 G. Daskal, C. Woodard, S. T. Crooke et al., Cancer Res. 38 (1978) 467.
- 310 W. E. Ross, L. A. Zwelling, K. W. Kohn, Int. J. Radiat. Oncol., Biol. Phys. 5 (1979) 1221.
- 311 B. Sinha, R. H. Sik, Biochem. Pharmacol. 29 (1980) 1867.
- 312 K. Handa, S. Sato, Gann 66 (1975) 43.
- 313 N. R. Bachur, S. L. Gordon, M. V. Gee, Cancer Res. 38 (1977) 1745.
- 314 R. Ogura, H. Toyama, T. Shimada et al., J. Appl. Biochem. 1 (1979) 325.
- 315 J. H. Doroshow, G. Y. Locker, C. E. Myers, J. Clin. Invest. 65 (1980) 128.
- 316 N. W. Revis, N. Marusic, J. Mol. Cell. Cardiol. 10 (1978) 945.
- 317 T. R. Tritton, S. A. Murphree, A. C. Sartorelli, Biochem. Biophys. Res. Commun. 84 (1978) 802.
- 318 T. R. Tritton, G. Yeh, Science 217 (1982) 248.
- 319 E. Goormaghtigh, R. Brasseur, J. M. Ruysschaert, Biochem. Biophys. Res. Commun. 104 (1982) 314.
- 320 C. E. Myers, C. Simone, L. Gianni et al., Proc. Am. Assoc. Cancer Res. 22 (1981) 112.
- 321 T. Oki, Jpn. J. Antibiot. 30 (1977) 570.
- 322 R. K. Y. Zee-Cheng, C. C. Cheng, J. Med. Chem. 21 (1978) 291.
- 323 L. H. Patterson, B. M. Gandecka, J. R. Brown, Biochem. Biophys. Res. Commun. 110 (1983) 399.
- 324 E. D. Kharasch, R. F. Novak, Biochem. Biophys. Res. Commun. 108 (1982) 1346.
- 325 S. S. Legha, Drugs Today 20 (1984) 12, 629 – 638.
- 326
Drugs of the Future
5
(1980)
234;
10.1358/dof.1980.005.05.201789 Google Scholar6 (1981) 316; 7 (1982) 357; 8 (1983) 64; 9 (1984) 380; 10 (1985) 429.
- 327 American Cyanamid, USP 4197249 ,1980 (F. E. Durr, K. C. Murdock).
- 328 R. K.-Y. Zee-Cheng, C. C. Cheng, J. Med.-Chem. 22 (1979) 1024.
- 329 K. C. Murdock et al., J. Med. Chem. 22 (1979) 9, 1024 – 1030.
- 330 F. I. Durr, R. E. Wallace, R. V. Citarella, Cancer Treat Rev. 10 (1983) 3 – 11.
- 331 R. E. Wallace, K. C. Murdock, R. B. Angier, F. E. Durr, Cancer Res. 39 (1979) 1570 – 1574.
- 332 R. K. Johnson et al., Cancer Treat. Rep. 63 (1979) 425 – 439.
- 333 D. D. Von Hoff, C. A. Coltuan, B. Forseth, Cancer Res. 41 (1981) 1853 – 1855.
- 334 B. M. Henderson et al., Cancer Treat. Rep. 66 (1982) 1139 – 1143.
- 335 B. M. Sparano, G. Gordon, C. Hall, M. J. Iatropoulos, J. F. Noble, Cancer Treat. Rep. 66 (1982) 1145 – 1158.
- 336 K. C. Anderson et al., Cancer Treat. Rep. 67 (1983) 435 – 438.
- 337 F. C. Schell et al., Cancer Treat. Rep. 66 (1982) 1641 – 1643.
- 338 C. B. Pratt et al., Cancer Treat. Rep. 67 (1983) 85 – 88.
- 339 D. V. Unverferth et al., Cancer Treat. Rep. 67 (1983) 343 – 350.
- 340 M. S. Aapro, D. S. Alberts, Invest. New Drugs 2 (1984) 329 – 330.
- 341 S. A. Taylor, B. T. Tranum, D. D. Von Hoff, J. J. Constanzi, Invest. New Drugs 3 (1985) 67 – 69.
- 342 J. A. Elliott et al., Anti-Cancer Drug Res. 3 (1989) 4, 271 – 282.
- 343 R. F. Marschke et al., Med. Pediat. Oncol. 16 (1988) 4, 269 – 270.
- 344
K. Hillier,
Drugs of the Future
6
(1981)
12,
762;
7
(1982)
896.
10.1358/dof.1981.006.12.75183 Google Scholar
- 345 K. C. Murdock et al., J. Med. Chem. 25 (1982) 505.
- 346 American Cyanamid, EP 338372 ,1989 (V. J. Lee, K. C. Murdock)
- 347 American Cyanamid, US 4900838 ,1990 (K. C. Murdock)
- 348 K. C. Murdock et al., J. Med. Chem. 36 (1993) 15, 2098.
- 349 US Dept. Of Health, USP 25157 ,1981 (H. Dubicki, J. L. Parsons, F. W. Starks).
- 350 B. F. Cain et al., J. Med. Chem. 18 (1975) 1110.
- 351 Annu. Drug Data Report (1981) 177.
- 352
Drugs of the Future
5
(1980)
277;
10.1358/dof.1980.005.06.154683 Google Scholar8 (1983) 535.
- 353 L. Steinherz et al., Cancer Treat. Rep. 66 (1982) 483.
- 354 J. Kolwas, Drugs Today 15 (1979) 200.
- 355 G. A. Curt, N. J. Clendeninn, B. A. Chabner, Cancer Treat. Rep. 68 (1984) 87 – 99.
- 356 T. Tsuruo, H. Lida, M. Nojiri, Cancer Res. 43 (1983) 2905.
- 357 S. Waksman, H. B. Woodruff, Proc. Soc. Exp. Biol. Med. 45 (1940) 609 – 611.
- 358 H. M. Sobell, S. C. Jam, T. D. Sakore et al., Nat. New Biol. 231 (1971) 200.
- 359 F. Takusagawa et al.: 12th Congress of the IUCR Associated Meeting on Molecular Structure and Biologic Activity, Buffalo, New York, August 26 – 28, 1981, p. 55.
- 360 E. Reich, R. M. Franklin, A. J. Shatkin et al., Proc. Natl. Acad. Sci. USA 48 (1982) 1238.
- 361 H. S. Schwartz, E. Godoyien, R. Y. Ambaye, Cancer Res. 287 (1968) 192.
- 362 M. N. Goldstein, K. Hamm, E. Amrod, Science 151 (1966) 1555 – 1556.
- 363 H. Umezawa, K. Meada, T. Takeuchi et al., J. Antibiot. Ser. A. 19 (1966) 200 – 206.
- 364 B. T. Sikic, Z. H. Siddik, T. E. Gram, Cancer Treat. Rep. 64 (1980) 659 – 667.
- 365 T. Takita, Y. Muraoka, H. Umezawa: “Bleomycin and Peplomycin,” in H. M. Pinedo, B. A. Chabner (eds.): Cancer Chemotherapy Annual 6, Elsevier, Amsterdam 1984, pp. 85 – 90.
- 366 A. Hagiwara et al., Anti-Cancer Drug Res. 2 (1988) 319 – 324.
- 367 S. Saito, Y. Umezawa, T. Yoshioka et al., J. Antibiot. (Tokyo) 36 (1983) 92 – 95.
- 368 J. Fugimito, H. Higashi, G. Kosaki, Cancer Res. 36 (1976) 2248 – 2251.
- 369 M. Chien, A. P. Grollman, S. B. Horwitz, Biochemistry 16 (1977) 3641 – 3645.
- 370 W. J. Caspay, C. Niziak, D. A. Lanzo et al., Mol. Pharmacol. 16 (1979) 256 – 260.
- 371 S. Biables, J. R. Warr, Genet. Res. 34 (1979) 269 – 279.
- 372 M. Mayaki, T. Ono, S. Hori et al., Cancer Res. 35 (1975) 2015 – 2018.
- 373 S. Akiyama, M. Kuwano, J. Cell Physiol. 107 (1981) 147 – 153.
- 374 S. Akiyama, K. Ikezaki, H. Kunamochi et al., Biochem. Biophys. Res. Commun. 101 (1981) 55 – 60.
- 375 W. E. G. Mueller, M. Geisort, R. K. Zahn et al., Eur. J. Cancer Clin. Oncol. 19 (1983) 665 – 669.
- 376 P. G. Sorensen, M. Dorth, H. H. Hansen, Eur. J. Cancer Clin. Oncol. 19 (1983) 319 – 323.
- 377 R. K. Johnson, R. P. Hertzberg, Annu. Rep. Med. Chem. 25 (1990) 129.
- 378 P. A. Aristoff et al., Invest. New Drugs 7 (1989) 364.
- 379 J. P. Mc Govren et al., Invest. New Drugs 7 (1989) 448.
- 380 M. A. Mitchell, P. D. Johnson, M. G. Williams, P. A. Aristoff, J. Am. Chem. Soc. 11 (1989) 6428.
- 381 K. Goni et al., Jpn. J. Cancer Res. 83 (1992) 113.
- 382 D. L. Boger, M. S. S. Palanki, J. Am. Chem. Soc. 114 (1992) 9318.
- 383 M. Fontana et al., Anti-Cancer Drug Res. 7 (1992) 131.
- 384 D. Volpe et al., Invest. New Drugs 10 (1992) 255.
- 385 N. Zein, M. Poncin, R. Nilakantan, G. A. Ellestad, Science 244 (1989) 697.
- 386 B. H. Long et al., Proc. Natl. Acad. Sci. USA 86 (1989) 2.
- 387 K. C. Nicolaou, Science 256 (1992) 1172.
- 388 K. C. Nicolaou, W. M. Dai, J. Am. Chem. Soc. 114 (1992) 8908.
- 389 W. A. Bleyer, S. A. Frisby, V. T. Oliverio, Biochem. Pharmacol. 24 (1979) 633 – 639.
- 390 R. A. Bender, W. D. Kornreich, Proc. Am. Assoc. Cancer Res. 22 (1981) 227.
- 391 H. Mujagic, S. S. Chen, R. Geist et al., Cancer Res. 43 (1983) 3591 – 3597.
- 392 D. V. Jackson, R. A. Bender, Cancer Res. 39 (1979) 4341 – 4349.
- 393 R. Schrek, Am. J. Clin. Path. 62 (1974) 1 – 7.
- 394 R. A. Bender, W. A. Bleyer, S. A. Frisby et al., Cancer Res. 35 (1975) 1305 – 1308.
- 395 R. F. Zager, S. A. Frisby, V. T. Oliverio, Cancer Res. 33 (1973) 1670 – 1676.
- 396 I. S. Johnson, H. F. Wright, G. H. Svoboda et al., Cancer Res. 20 (1980) 1016 – 1022.
- 397 G. A. Curt, B. D. Bailey, H. Mujagic et al., Proc. Am. Assoc. Cancer Res. 25 (1984) 337.
- 398 W. T. Beck, M. C. Cirtain, J. L. Lefko, Cancer Treat. Rep. 67 (1983) 875 – 879.
- 399 R. B. Sklaroff, D. Straus, C. Young, Cancer Treat. Rep. 63 (1979) 793 – 794.
- 400 G. Mathe, J. L. Misset, F. deVassal et al., Cancer Treat. Rep. 62 (1978) 805.
- 401 M. Bayssas, J. Gouveia, F. deVassal et al., Cancer Res. 74 (1980) 91 – 99.
- 402 R. Z. Andriamialisoa, N. Langlois, Y. Langlois, P. Potier, Tetrahedron 36 (1980) 3053 – 3060.
- 403
M. N. Serradel,
J. Castañer,
Drugs of the Future
11
(1986)
7,
575 – 577.
10.1358/dof.1986.011.07.50257 Google Scholar
- 404 M. R. Paintrand, I. Pignot, J. Electron. Microsc. 32 (1983) 2, 115 – 124.
- 405 P. Mangeney et al., J. Org. Chem. 44 (1979) 3765 – 3768.
- 406 P. Maral, C. Bourut, E. Chenn, G. Mathe, Cancer Chemother. Pharmacol. 5 (1981) 3, 197 – 199.
- 407 R. Maral, C. Bourut, E. Chenn, G. Mathe, Cancer Lett. 22 (1984) 49 – 54.
- 408 G. Mathe, P. Reizenstein, Cancer Lett. 27 (1985) 285 – 293.
- 409 M. Besenval et al., Semin. Oncol. 16 (1989) 2, 37.
- 410 A. Depierre et al., Semin. Oncol. 16 (1989) 2, 26.
- 411 J. B. Sorensen, Drugs 44 (1992) 60.
- 412 P. B. Schiff, A. S. Kende, S. B. Horwitz, Biochem. Biophys. Res. Commun. 85 (1978) 737 – 740.
- 413 R. A. Bender, B. A. Chabner: “Tubulin Binding Agents: Epipodophyllotoxin,” in B. A. Chabner (ed.): Pharmacologic Principles of Cancer Treatment, W. B. Saunders, Philadelphia 1982, pp. 263 – 266.
- 414 J. D. Loike, S. B. Horwitz, Biochemistry 15 (1976) 5435 – 5438.
- 415 D. K. Kalwinsky, A. T. Look, J. Ducore, A. Fridland, Cancer Res. 43 (1983) 1592 – 1596.
- 416 A. J. Wozniak, W. E. Ross, Cancer Res. 43 (1983) 130 – 135.
- 417 A. J. Wozniak, B. S. Glisson, K. R. Hande, W. E. Ross, Cancer Res. 44 (1984) 626 – 629.
- 418 B. H. Long, A. Minocha, Proc. Am. Assoc. Cancer Res. 24 (1983) 321.
- 419 M. E. Wall, M. C. Wani, C. E. Cook, K. H. Palmer, J. Am. Chem. Soc. 88 (1966) 3888.
- 420 J.-C. Cai, C. R. Hutchinson, Chem. Heterocyl. Compd. 25 (1983) 753.
- 421 Yakult Honsha, EP 137145 ,1985 (T. Miyasaka et al.).
- 422 Smith Kline Beecham Corp., EP 321122 (J. C. Boehm, S. M. Hecht, K. G. Holden, R. K. Johnson, W. D. Kingsbury).
- 423 W. D. Kingsbury et al., J. Med. Chem. 34 (1991) 98 – 107.
- 424 N. Osheroff, Pharmacol. Ther. 41 (1989) 223 – 41.
- 425 L. Liu, J. Wang, Proc. Natl. Acad. Sci. USA 84 (1987) 7024 – 7027.
- 426 A. J. Ryan, S. Squires, H. L. Strutt, R. T. Johnson, Nucl. Acid Res. 19 (1991) 12, 3295 – 3300.
- 427
M. N. Serradel,
J. Castañer,
R. M. Castañer,
Drugs of the Future
12
(1987)
3,
207.
10.1358/dof.1987.012.03.50861 Google Scholar
- 428
C. H. Spiridonis,
Drugs of the Future
20
(1995)
5,
483 – 489.
10.1358/dof.1995.020.05.298942 Google Scholar
- 429 W. J. Slichenmyer, E. K. Rowinsky, R. C. Donehower, S. H. Kaufmann, J. Natl. Cancer Inst. 85 (1993) 4, 271 – 291.
- 430 C. B. Hendricks et al., Cancer Res. 52 (1992) 8, 2268 – 2278.
- 431 W. K. Eng et al., Mol. Pharmacol. 38 (1990) 4, 471 – 480.
- 432 D. Abigerges et al., J. Natl. Cancer Inst. 86 (1994) 446.
- 433 M. C. Wani et al., J. Am. Chem. Soc. 93 (1971) 2325 – 2327.
- 434 J.-N. Denis et al., J. Am. Chem. Soc. 110 (1988) 5917 – 5919.
- 435 J.-N. Denis, A. Correa, A. E. Greene, J. Org. Chem. 55 (1990) 1957 – 1959.
- 436
M. Hepperle,
G. I. Georg,
Drugs of the Future
19
(1994)
573 – 584.
10.1358/dof.1994.019.06.595791 Google Scholar
- 437 K. C. Nicolaou, W. M. Dai, R. K. Guy, Angew. Chem. 106 (1994) 38 – 69.
- 438 K. C. Nicolaou et al., Nature 367 (1994) 630 – 634.
- 439 R. A. Holton et al., J. Am. Chem. Soc. 116 (1994) 1599 – 1600.
- 440
J. J. Masters
et al.,
Angew. Chem.
107
(1995)
1883.
10.1002/ange.19951071616 Google Scholar
- 441 P. B. Schiff, S. B. Horwitz, Proc. Natl. Acad. Sci. USA 77 (1980) 1561 – 1564.
- 442 P. B. Schiff, S. B. Horwitz, J. Cell Biol. 91 (1981) 479 – 483.
- 443 M. A. Bissery, D. Guenard, F. Gueritte-Voegelein, F. Lavelle, Cancer Res. 51 (1991) 4845 – 4852.
- 444 I. Ringel, S. B. Horwitz, J. Natl. Cancer Inst. 83 (1991) 288 – 291.
- 445 R. Pazdur et al., Cancer Treat. Rev. 19 (1993) 351 – 386.
- 446 P. B. Schiff, J. Faut, S. B. Horwitz, Pharmacol. Ther. 25 (1984) 83 – 124.
- 447 S. Rao, J. J. Manfredi, S. B. Horwitz, I. Ringel, J. Natl. Cancer Inst. 84 (1992) 785 – 788.
- 448 S. Rao, S. B. Horwitz, I. Ringel, J. Natl. Cancer Inst. 84 (1992) 785 – 788.
- 449 J. Parness, S. B. Horwitz, J. Cell. Biol. 91 (1981) 479 – 487.
- 450 P. B. Schiff, S. B. Horwitz, Biochemistry 20 (1981) 3247 – 3252.
- 451 A. H. Ding, F. Porten, E. Sanchez, C. F. Nathan, Science 248 (1990) 370 – 372.
- 452 C. Bogdan, A. Ding, J. Leukocyte Biol. 52 (1992) 119 – 121.
- 453 M. E. Stearns, M. Wang, Cancer Res. 52 (1992) 3776 – 3781.
- 454 D. M. Vyas et al., Biorg. Med. Chem. Lett. 3 (1993) 1357 – 1360.
- 455 E. K. Rowinsky et al., Semin. Oncol. 20 (1993) 3, 1 – 15.
- 456 H. Lataste et al., Proc. Natl. Acad. Sci. USA 81 (1984) 4090 – 4094.
- 457 J. Kant et al., Biorg. Med. Chem. Lett. 3 (1993) 2471 – 2474.
- 458 G. Samaranayake, N. F. Magri, C. Jitransgri, D. G. Kingston J. Org. Chem. 56 (1991) 5114 – 5119.
- 459 A. Datta, L. Jayasinghe, G. I. Georg, J. Med. Chem. (1994) 4258 – 4260.
- 460
J. L. Fabre,
D. Lolli-Tonelli, L. H. Spiridonidis,
Drugs of the Future
20
(1995)
5,
464.
10.1358/dof.1995.020.05.296696 Google Scholar
- 461 Annual Data Report (1995) 765.
- 462
G. Höfle
et al.,
Angew. Chem.
108
(1996)
1671;
10.1002/ange.19961081342 Google ScholarInt. Ed. Engl. 35 (1996) 1567.
- 463 D. M. Bollag et al., Cancer Res. 55 (1995) 2325 – 2333.
- 464
A. Bolag
et al.,
Angew. Chem.
108
(1996)
2976;
10.1002/ange.19961082318 Google ScholarInt. Ed. Engl. 35 (1996) 2801.
- 465 D. Meng et al., J. Amer. Chem. Soc. 119 (1997) 2733.
- 466 K. C. Nicolaou et al., Angew. Chem. 108 (1996) 2534.
- 467 K. C. Nicolaou et al., Nature 387 (1997) 268 – 272.
- 468
D. Schinzer
et al.,
Angew. Chem.
109
(1997)
543 – 544.
10.1002/ange.19971090525 Google Scholar
- 469 D.-S. Su et al., Angew. Chem. 109 (1997) 2178.
- 470 R. J. Kowalski et al., J. Biol. Chem. 272 (1997) 2534.
- 471 B. Rosenberg, L. Van Camp, T. Krigas, Nature (London) 205 (1965) 698 – 700.
- 472 B. Rosenberg, L. Van Camp, J. E. Troska et al., Nature (London) 222 (1969) 385 – 386.
- 473
A. H. Rossof,
R. E. Slayton,
C. P. Perlia,
Cancer
30
(1972)
1451 – 1455.
10.1002/1097-0142(197212)30:6<1451::AID-CNCR2820300606>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 474 D. J. Higby, H. J. Wallace Jr., J. F. Holland, Cancer Chemother. Rep. 57 (1973) 459 – 463.
- 475 L. H. Einhorn, S. D. Williams, N. Engl. J. Med. 300 (1979) 289 – 292.
- 476 A. W. Prestayko, J. C. D'Aousst, B. F. Issel et al., Cancer Treat. Rev. 6 (1979) 17 – 24.
- 477 W. M. Scovell, T. O'Connor, J. Am. Chem. Soc. 99 (1977) 120 – 126.
- 478 A. F. LeRoy, R. J. Lutz, R. L. Dedrick et al., Cancer Treat. Rep. 63 (1979) 59 – 64.
- 479 G. L. Cohen, W. R. Bauer, J. K. Berton et al., Science 203 (1979) 1014 – 1016.
- 480 R. C. Srivastava, J. Froelich, G. L. Eichhorn, Biochimie 60 (1979) 879 – 881.
- 481 J. J. Roberts, A. J. Thomson, Prog. Nucleic Acid Res. Mol. Biol. 22 (1979) 71 – 133.
- 482 B. Rosenberg, Naturwissenschaften 60 (1973) 399 – 408.
- 483 T. F. Slater, M. Ahmed, S. A. Ibrahim, J. Clin. Hematol. Oncol. 7 (1977) 534 – 539.
- 484 N. E. Madias, J. T. Harrington, Am. J. Med. 65 (1978) 307 – 311.
- 485 D. C. Dobyan, J. Levi, C. Jacobs et al., J. Pharmacol. Exp. Therap. 213 (1980) 551 – 556.
- 486 R. L. Schilsky, T. Anderson, Ann. Intern. Med. 90 (1979) 929 – 931.
- 487 F. A. Hayes, A. A. Green, N. Jenzen et al., Cancer Treat. Rep. 63 (1979) 547 – 549.
- 488 S. Davis, W. Kessler, B. M. Haddad et al., J. Med. 11 (1980) 133 – 137.
- 489
M. Dentino,
F. L. Luft,
M. N. Yum
et al.,
Cancer
41
(1978)
1274 – 1279.
10.1002/1097-0142(197804)41:4<1274::AID-CNCR2820410410>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 490 K. K. Chang, D. J. Higby, E. S. Henderson et al., Cancer Treat. Rep. 61 (1977) 367 – 371.
- 491 R. F. Ozols, B. Corden, J. Jacobs et al., Ann. Intern. Med. 100 (1984) 19 – 24.
- 492 J. Drobnik, M. Urbankova, A. Krekulova, Mut. Res. 17 (1973) 13 – 20.
- 493 L. A. Zwelling, S. Michaels, H. Schwartz, Cancer Res. 41 (1981) 640 – 649.
- 494 J. Ducore, L. Zwelling, K. Kohn, Proc. Am. Assoc. Cancer Res. 21 (1980) 267.
- 495 L. C. Erikson, L. A. Zwelling, J. M. Ducore, Cancer Res. 4 (1981) 2791 – 2794.
- 496 K. Micetich, S. Michaels, G. Jude et al., Proc. Am. Assoc. Cancer Res. 22 (1981) 252.
- 497 A. Bakka, L. Endresen, A. B. S. Johnson et al., Toxicol. Appl. Pharmacol. 61 (1981) 215 – 226.
- 498 L. R. Beach, R. D. Palmiter, Proc. Natl. Acad. Sci. USA 78 (1981) 2110 – 2114.
- 499 C. R. Wilkenson, P. J. Cox, M. Jones et al., Biochimie 60 (1978) 851 – 857.
- 500
Drugs of the Future
8
(1983)
489;
10.1358/dof.1983.008.06.55727 Google Scholar9 (1984) 463; 10 (1985) 497; 11 (1986) 499.
- 501 Drugs Today 22 (1986) 255.
- 502 Research Corp., DE 2 329 485, 1973 (M. J. Cleare, J. D. Hoeschele, B. Rosenberg).
- 503 R. C. Harrison et al., Inorg. Chim. Acta 46 (1980) 215.
- 504 A. H. Calvert et al., Cancer Chemother. Pharmacol. 9 (1982) 140.
- 505 B. D. Evans et al., Proc. Ass. Cancer Res. 24 (1983) 154.
- 506 CBDCA, Clinical Brochure, Investigational Drug Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md., 1980.
- 507 B. D. Evans, K. S. Raju, A. H. Calvert, S. U. Harland et al., Cancer Treat. Rep. 67 (1983) 997 – 1001.
- 508 P. J. Creaven, S. Madajewicz, L. Pendyala et al., Cancer Treat. Rep. 67 (1983) 795 – 798.
- 509 C. Sternberg et al., Cancer Treat. Rep. 69 (1985) 1305 – 1307.
- 510 R. Canetta et al., Cancer Treat. Rep. 63 (1985) 2107 – 2109.
- 511 I. N. Olver et al., Cancer Treat. Rep. 70 (1986) 421 – 422.
- 512 A. P. Kyriazis et al., Cancer res. 45 (1985) 2012 – 2015.
- 513 K. R. Harrap, M. Jones, C. R. Wilkenson et al.: “Antitumor Toxic and Biochemical Properties of cis-Platinum and Eight Other Platinum Analogs,” in A. W. Prestayko, S. T. Crooke, S. K. Carter (eds.): cis-Platinum: Current Status and New Developments (Pap Symposium), Academic Press, New York 1980, pp. 193 – 212.
- 514 P. Chang, Drugs of the Future 8 (1983) 364; 10 (1985) 7, 561.
- 515 Drugs of the Future 12 (1987) 11, 1029 – 1031.
- 516 Annu. Drug Data Rep. 8 (1986) 6, 590.
- 517 Shionogi & Co., EP 216362 1987 (H. Kagawa, K. Shima, T. Tsukada).
- 518
K. Hirabayashi,
E. Okada,
Cancer
71
(1993)
9,
2769.
10.1002/1097-0142(19930501)71:9<2769::AID-CNCR2820710914>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 519 M. Koenuma et al., Clin. Rep. 29 (1995) 12, 259.
- 520 N. Uchida et al., Clin. Rep. 29 (1995) 12, 269.
- 521 I. H. Krakoff, 5th Intl. Symp. Platinum Cancer Chemother., Abano Therme, 1987, Abst. L7.
- 522 B. K. Bhuyan et al., Cancer Commun. 3 (1991) 2, 53.
- 523 ASTA Medica AG, EP 324154 1989 (J. Engel et al.).
- 524
R. Voegeli,
E. Günther,
P. Aulenbacher,
J. Engel,
P. Hilgard,
Drugs of the Future
17
(1992)
883 – 886.
10.1358/dof.1992.017.10.183955 Google Scholar
- 525 A. M. Otto et al., Pharm. Pharmacol. Lett. 1 (1992) 103 – 106.
- 526 W. A. Denny et al., J. Med. Chem. 35 (1992) 2983 – 2987.
- 527 Drugs Today 10 (1974) 74.
- 528 ICI, GB 1013907 1962.
- 529 G. R. Bedford, D. N. Richardson, Nature 212 (1966) 733.
- 530
M. N. Serradel,
J. Castañer,
Drugs of the Future
11
(1986)
5,
398 – 400.
10.1358/dof.1986.011.05.52342 Google Scholar
- 531 Farmos Group, EP 95875 (R. J. Tiovola et al.).
- 532
J. T. Pento
et al.,
Drugs of the Future
9
(1984)
7,
5.
10.1358/dof.1984.009.07.66421 Google Scholar
- 533
R. Löser,
P.-St. Jamak,
K. Seibel,
Drugs of the Future
9
(1984)
3,
186.
10.1358/dof.1984.009.03.63597 Google Scholar
- 534 S. Kallio et al., Cancer Chemother. Pharmacol. 17 (1986) 103 – 108.
- 535 L. Kangas et al., Cancer Chemother. Pharmacol. 17 (1986) 109 – 113.
- 536 V. C. Jordan, B. Gosden, Mol. Cell. Endocrinol. 27 (1982) 27, 921.
- 537 S. P. Robinson et al., Eur. J. Cancer Clin. Oncol. 24 (1988) 12, 1817.
- 538 R. Valavaara et al., Eur. J. Cancer Clin. Oncol. 24 (1988) 4, 785.
- 539 S. R. Ebbs et al., Lancet II (1987) 621.
- 540 R. F. Kauffmann et al., J. Pharmacol. Exp. Ther. 280 (1997) 146 – 153.
- 541 M. A. Ferreira, M. M. Caramona, L. M. Celeste, Proc. Br. Pharmacol. Soc. (1995) Abs. 267 P.
- 542 M. Dukes, Pharm. J. 257 (1996) 176.
- 543
A. Hoshi,
Drugs of the Future
16
(1991)
3,
217.
10.1358/dof.1991.016.03.869528 Google Scholar
- 544 Annu. Drug Data Report 15 (1993) 4, 378.
- 545 A. Brodie, J. Steroid Biochem. Mol. Biol. 40 (1991) 1 – 3, 255.
- 546 S. A. Wells et al., Cancer Res. Suppl. 42 (1982) 3454.
- 547 R. D. Burnett, D. N. Kirk, J. Chem. Soc. Perkin Trans. I (1973) 1830.
- 548 R. C. Coombes, Eur. J. Cancer 28A (1992) 12, 1941.
- 549
D. Cunningham
et al.,
Brit. J. Cancer
55
(1987)
331.
10.1038/bjc.1987.65 Google Scholar
- 550 J. H. Davis et al., Brit. J. Cancer 66 (1992) 1, 139.
- 551 M. Dowsett et al., Cancer Res. 49 (1989) 1306.
- 552 M. Dowsett et al., Eur. J. Cancer 28 (1992) 2 – 3, 415.
- 553 R. C. Stein et al., Cancer Chemother. Pharmacol. 26 (1990) 75.
- 554 ICI, US 4935437 ,1990 (P. N. Edwards, M. S. Lange).
- 555 Ciba Geigy AG, US 4617307 ,1986 (L. J. Browne).
- 556
J. Prous,
Drugs of the Future
19
(1994)
4,
335 – 337.
10.1358/dof.1994.019.04.245953 Google Scholar
- 557 J. Castañer, Annu. Drug Data Rep. 13 (1991) 8, 716.
- 558 A. B. Foster et al., J. Med. Chem. 28 (1985) 200.
- 559
J. T. Pento,
Drugs of the Future
14
(1989)
9,
843 – 845.
10.1358/dof.1989.014.09.103414 Google Scholar
- 560
J. Prous
et al.,
Drugs of the Future
20
(1995)
1,
30 – 32.
10.1358/dof.1995.020.01.279991 Google Scholar
- 561 R. E. Steele et al., Steroids 50 (1987) 147.
- 562 M. Dukes et al., Proc. Am. Assoc. Cancer Res. 33 (1992) Abst. 1677.
- 563 P. V. Plourde et al., Breast Cancer Res. Treat. 30 (1994) 1, 103 – 111.
- 564 K. Schieweck, A. S. Bhatnagar, A. Matter, Cancer Res. 48 (1988) 834.
- 565 K. Schieweck et al., Proc. Am. Assoc. Cancer Res. 29 (1988) Abst. 968.
- 566 M. Dowsett et al., Breast Cancer Res. Treat. 27 (1993) 1 – 2, Abst. 87.
- 567 P. V. Plourde et al., Proc. Am. Soc. Clin. Oncol. 12 (1993) Abst. 165.
- 568 C. Huggins, C. V. Hodges, Cancer Res. 1 (1941) 293.
- 569 J. A. Smith, J. Urol. 137 (1987) 1 – 10.
- 570 J. Trachtenberg, J. Urol. 132 (1984) 61.
- 571 G. H. Rasmusson et al., J. Med. Chem. 27 (1984) 1690 – 1701.
- 572 M. R. Robinson, B. S. Thomas, Brit. Med. J. 4 (1971) 391 – 394.
- 573 F. Neumann, J. Steroid Biochem. 19 (1983) 391 – 402.
- 574 B. J. Furr, Clin. Oncol. 2 (1988) 581 – 590.
- 575
H. Tucker,
Drugs of the Future
15
(1990)
3,
255 – 265.
10.1358/dof.1990.015.03.115229 Google Scholar
- 576 Drugs Today 20 (1984) 296.
- 577
Drugs of the Future
1
(1976)
108;
10.1358/dof.1976.001.03.199330 Google Scholar8 (1983) 270.
- 578 R. O. Neri, E. A. Peets, J. Steroid Biochem. 6 (1975) 815 – 819.
- 579 W. I. P. Mainwaring, F. R. Mangan, P. A. Feherty, M. Freifeld, Med. Cell. Endocrinol. 1 (1974) 113 – 128.
- 580 S. Liao, D. K. Howell, T. M. Chang, Endocrinology 94 (1974) 1205 – 1209.
- 581 B. Katchen, S. Buxbaum, J. Clin. Endocrinol. Metab. 41 (1975) 373 – 379.
- 582 J. Geller et al., Prostate 2 (1981) 309 – 314.
- 583 E. A. Peets, M. F. Henson, R. O. Neri, Endocrinology 94 (1974) 532 – 540.
- 584 R. Neri, N. Kassem, Prog. Cancer Res. Ther. 31 (1984) 507 – 518.
- 585 F. Labrie et al., Oncol. 2 (1988) 597 – 619.
- 586 F. Labrie, A. Dupont, M. Ciguere, Brit. J. Urol. 61 (1988) 341 – 346.
- 587 A. Belanger, A. Dupont, F. Labrie, J. Clin. Endocrinol. Metab. 59 (1984) 422 – 426.
- 588 J.-P. Raynaud, C. Bonne et al., Prostate 5 (1984) 299 – 311.
- 589
T. Ojasoo,
Drugs of the Future
12
(1987)
763 – 770.
10.1358/dof.1987.012.08.49902 Google Scholar
- 590 L. Proulx, F. Labrie, Prostate 5 (1984) Abst. 429.
- 591 F. Labrie, A. Dupont, A. Belanger, Prostate 4 (1983) 579.
- 592 C. Harnois, A. Dupont, F. Labrie, Brit. J. Opthalmol. 70 (1986) 471 – 473.
- 593 H. Tucker, G. J. Chesterson, J. Med. Chem. 31 (1988) 885 – 887.
- 594 H. Tucker, J. W. Crook, G. J. Chesterson, J. Med. Chem. 31 (1988) 954 – 959.
- 595 B. J. A. Furr et al., J. Endocrinol. 113 (1987) R7 – 9.
- 596 S. N. Freeman, W. I. P. Mainwaring, B. J. A. Furr, J. Endocrinol. (1986) Suppl. III, 155.
- 597 C. J. Tyrell, Prostate (Suppl. 4) 20 (1992) 97.
- 598 G. Wilding et al., Proc. Am. Assoc. Clin. Oncol. 10 (1991) Abst. 593.
- 599 A. V. Schally, S. M. McCann, Fertil. Steril. 64 (1995) 452 – 453.
- 600 A. V. Schally, A. Arimura, A. J. Kastin, Science 173 (1971) 1036 – 1038.
- 601 H. Matsuo, Y. Baba, M. Nair, A. Arimura, A. V. Schally, Biochem. Biophys. Res. Commun. 43 (1971) 1334 – 1339.
- 602 K. Amoss et al., Biochem. Biophys. Res. Commun. 44 (1971) 205 – 210.
- 603 Y. Baba, H. Matsuo, A. V. Schally, Biochem. Biophys. Res. Commun. 44 (1971) 459 – 463.
- 604 G. Emons, A. V. Schally, Hum. Reprod. 9 (1994) 1364 – 1370.
- 605 P. M. Conn, W. Crowley, New Engl. J. Med. 324 (1991) 93 – 103.
- 606
G. F. Weinbauer,
E. Nieschlag in
K. Höffgen (ed.):
Peptides in Oncology,
Springer, Heidelberg
1992,
pp. 113 – 136.
10.1007/978-88-470-2186-0_11 Google Scholar
- 607 A. S. Dutta, Drugs of the Future 13 (1988) 43 – 57.
- 608 M. Filicori, C. Flamingi, Drugs 35 (1988) 63 – 82.
- 609 J. J. Nestor, B. H. Vickery, Annu. Rep. Med. Chem. 23 (1988) 211 – 220.
- 610 M. T. Goulet, Annu. Rep. Med. Chem. 30 (1995) 169 – 178.
- 611 T. Reissmann et al., Hum. Reprod. 20 (1995) 1974 – 1981.
- 612 M. J. Karten in W. F. Crowley, P. M. Conn (eds.): Modes of Action of GnRH and GnRH Analogs, Springer, Heidelberg 1992, pp. 277 – 297.
- 613 G. Flouret et al., Pept. Sci. 1 (1995) 89 – 105.
- 614 P. M. Conn, W. F. Crowley, Annu. Rev. Med. 45 (1994) 391.
- 615 A. V. Schally in J. F. Holand et al. (eds): Cancer Medicine 3rd ed., Lee & Febiger, Philadelphia, PA 1993 pp. 827 – 840.
- 616 A. V. Schally in P. Belfort, J. Pinotti, T. K. Eskes (eds.): Advances in Gynecology and Obstetrics Vol. 6, Parthenon, Cornforth 1989, pp. 3 – 22; b) Scrip 22, 1995, 2066.
- 617 A. Friedrich, G. Jaeger, K. Radscheit, R. Uhmann, Pept. Proc. Eur. Pept. Symp. 22nd 1992/1993, 47 – 49.
- 618 B. Kutscher et al., Angew. Chem. Int. Ed. Engl. 36 (1997) 2148 – 2161.
- 619 R. L. Barbieri, Trends Endocrinol. Metab. 3 (1992) 30 – 34.
- 620 R. Schmidt, K. Sundaram, R. B. Thau, C. W. Badrin, Contraception 29 (1984) 283 – 289.
- 621 S. Bajusz et al., Int. J. Pept. Protein Res. 32 (1988) 425 – 435.
- 622 J. Pinski et al., Int. J. Pept. Protein Res. 45 (1995) 410 – 417.
- 623 A. Kleemann et al., Proc. Akabori Conf. Ger. Jpn. Symp. Pept. Chem. 4th 1991, 96 – 101; b) F. R. Kunz, T. Müller, K. Drauz, Proc. Akabori. Conf. Ger. Jpn. Symp. Pept. Chem. 5th 1994, 15 – 16.
- 624 A. Ljugquist et al., Proc. Natl. Acad. Sci. USA 85 (1988) 8236 – 8240.
- 625
J. Leal
et al.,
Drugs of the Future
16
(1991)
529 – 537.
10.1358/dof.1991.016.06.161190 Google Scholar
- 626 A. Janecka, T. Janecki, C. Bowers, K. Folkers, J. Med. Chem. 37 (1994) 2238 – 2241.
- 627 A. Janecka et al., Med. Chem. Res. 1 (1991) 306 – 311.
- 628 A. Janecka, T. Janecki, C. Bowers, K. Folkers, Int. J. Pept. Protein Res. 44 (1994) 19 – 23.
- 629 P. Theobald et al., J. Med. Chem. 34 (1991) 2395 – 2402.
- 630 J. Rivier et al., J. Med. Chem. 35 (1992) 4270 – 4278.
- 631 J. E. Rivier et al., J. Med. Chem. 38 (1995) 2649 – 2662.
- 632 K. Stoeckemann, J. Sandow, J. Cancer Res. Clin. Oncol. 119 (1993) 457 – 462.
- 633 R. Deghenghi, F. Boutignon, P. Wüthrich V. Lenaerts, Biomed. Pharmacother. 47 (1993) 107 – 110.
- 634 J. Nester, et al., J. Med. Chem. 35 (1992) 3942 – 3948.
- 635
J. Mulzer in
E. Ottow,
U. Schöllkopf,
B. G. Schulz (eds.):
Stereoselective Synthesis,
Springer, Heidelberg
1994,
pp. 37 – 61.
10.1007/978-3-642-78496-5_3 Google Scholar
- 636 J. Mulzer et al., Angew. Chem. 106 (1994) 1813 – 1815; Angew. Chem. Int. Ed. Engl. 33 (1994) 1737 – 1739.
- 637 F. Haviv et al., J. Med. Chem. 32 (1989) 2340 – 2344.
- 638 F. Haviv et al., J. Med. Chem. 36 (1993) 928 – 933.
- 639 Abbott Laboratories, PCT/US 95/02410 ,1995 (F. Haviv).
- 640 Abbott Laboratories, WO 95/04540 ,1995 (F. Haviv).
- 641 Abbott Laboratories, WO 94/14841 ,1994 (F. Haviv).
- 642 Abbott Laboratories, WO 94/13313 ,1994 (J. Greer).
- 643 Tap Pharmaceuticals, US-A 5300492 ,1994 (F. Haviv).
- 644 F. Haviv et al., J. Med. Chem. 37 (1994) 701 – 707.
- 645 T. Beckers, K. Marheineke, H. Reiländer, P. Hilgard, Eur. J. Biochem. 231 (1995) 535 – 543.
- 646 R. P. Millar, C. A. Flanagan, R. C. Milton, J. A. King, J. Biol. Chem. 264 (1989) 21007 – 21013.
- 647 G. A. McPherson, J. Pharmacol. Methods 14 (1985) 213 – 228.
- 648 J. Trachtenberg, A. Pont, Lancet 2 (1984) 433 – 435.
- 649 S. Bhasin et al., Endocrinology 118 (1986) 1229 – 1232.
- 650 B. De et al., J. Med. Chem. 32 (1989) 2036 – 2038.
- 651 Abbott Laboratories, US-A 4992421 ,1991 (B. De).
- 652 McNeillab Inc., US-A 4678784 ,1987 (C. Y. Ho).
- 653 Takeda Chemical Industries, WO 95/28405 ,1995 (S. Furuya).
- 654 Takeda Chemical Industries, WO 96/34012A1 ,1996 (C. Kitada).
- 655 Merck, WO 97/21435 ,1997 (M. Goulet).
- 656 Takeda Chemical Industries, WO 97/14697 ,1997 (S. Furuya).
- 657 C. Unger, Drugs of the Future 22 (1997) 12, 1337 – 1345.
- 658 G. Powis, Pharmacol. Ther. 62 (1994) 57 – 95.
- 659 W. J. Fantl, D. E. Johnson, L. T. Williams, Annu. rev. Biochem. 62 (1993) 453 – 481.
- 660 F. McCormick, Nature 363 (1993) 15 – 16.
- 661 C. A. Lang-Carter et al., Science 260 (1993) 315 – 319.
- 662 D. Rea et al., Proc. 7th NCI-EORTC Symp. On New Drugs in Cancer Ther. Amsterdam (1992), p. 62.
- 663 D. Ingber et al., Nature 348 (1990) 555.
- 664
T. Ozsuka
et al.,
J. Antibiotics
45
(1992)
348.
10.7164/antibiotics.45.348 Google Scholar
- 665 Y. Reiss et al., Cell 62 (1990) 81 – 88.
- 666 S. Omura, D. van der Pyl, Cell 46 (1993) 222.
- 667 S. M. Sebti, A. D. Hamilton, Drug Discovery Technol. 3 (1998) 26 – 33.
- 668 A. Levitski, A. Gazit, Science 267 (1995) 1782 – 1788.
- 669 A. Levitski, Eur. J. Biochem. 226 (1994) 1 – 13.
- 670 R. T. Abraham, M. Aquarone, A. Anderson, Biol. Cell. 83 (1995) 105.
- 671 D. J. Hanahan, Ann. Rev. Biochem. 55 (1986) 483 – 509.
- 672 W. E. Berdel, Onkologie 13 (1990) 245 – 250.
- 673 W. E. Berdel et al., Anticancer Res. 1 (1981) 345 – 352.
- 674 G. Rodriguez et al., Proc. Am. Assoc. Cancer Res. 33 (1992) 262.
- 675 C. Unger, H. Eibl, Lipids 26 (1991) 1412.
- 676 P. Hilgard, J. Engel, Drugs Today Suppl. B., (1994) 30.
- 677 P. Hilgard et al., Cancer Chemother. Pharmacol. 32 (1993) 90 – 95.
- 678 P. Hilgard, J. Stekar, C. Unger, Proc. Annu. Meet. Am. Assoc. Cancer Res. 31 (1990) A2457.
- 679
J. Engel
et al.,
Drugs of the Future
13
(1988)
10,
948 – 951.
10.1358/dof.1988.013.11.72699 Google Scholar
- 680 C. Geilen et al., Eur. J. Cancer 27 (1991) 12, 1650 – 1653.
- 681 R. Hass et al., Cancer Res. 52 (1992) 1445 – 1450.
- 682 R. Becher et al., Onkologie 16 (1993) 1, 11.
